Andere talen Matinas BioPharma Holdings, Inc.

Aandelen

MTNB

US5768101058

Beurs gesloten - Nyse Andere beurzen 22:00:00 06-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,168 ^USD	-3,95%		-8,45%	-22,29%

30/04	In vivo werkzaamheid van Matinas BioPharma's orale MAT2203 bij longmucormycose gepubliceerd in Journal of Antimicrobial Agents and Chemotherapy	CI
27/03	Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting	14:00
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024	02/05
In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	01/05
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	30/04
In Vivo Efficacy of Matinas BioPharma?s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	30/04
Matinas BioPharma Prices $10 Million Registered Direct Offering	03/04
Matinas BioPharma Prices $10 Million Registered Direct Offering	03/04
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	27/03
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update	27/03
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate, Expanded Use Access Program Achieve Complete Clinical Response	25/03
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	25/03
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	25/03
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation	25/03
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation	25/03
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response	22/03
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	22/03
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards	22/03
North American Morning Briefing : Markets on Hold -2-	20/03
North American Morning Briefing : Stock Futures -2-	13/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Matinas BioPharma Holdings, Inc.

Aandelen

MTNB

US5768101058

Andere talen

Filters